GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age

Phase 2

Completed

Conditions: Diphtheria
Haemophilus Influenzae Type b
Tetanus
Poliomyelitis
Acellular Pertussis
Hepatitis B

First Posted Date: 2006-09-15

Last Posted Date: 2016-11-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 450

Registration Number: NCT00376779

Locations: 🇫🇮
GSK Investigational Site, Vantaa, Finland

The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain

Phase 2

Completed

Conditions: Neuropathic Pain

First Posted Date: 2006-09-14

Last Posted Date: 2013-02-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 113

Registration Number: NCT00376454

Locations: 🇺🇸
GSK Clinical Trials Call Center, Madison, Wisconsin, United States

Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2

First Posted Date: 2006-09-14

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 13

Registration Number: NCT00376038

Locations: 🇲🇽
GSK Investigational Site, Mexico, D.F., Mexico

Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer
Benign Prostatic Hyperplasia

First Posted Date: 2006-09-13

Last Posted Date: 2017-01-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT00375765

Locations: 🇳🇱
GSK Investigational Site, Nijmegen, Netherlands

Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: GSK1247446A
Biological: Fluarix™

First Posted Date: 2006-09-12

Last Posted Date: 2018-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 300

Registration Number: NCT00374842

Locations: 🇧🇪
GSK Investigational Site, Wilrijk, Belgium

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Phase 3

Completed

Conditions: Neoplasms, Breast

Interventions: Other: placebo
Drug: lapatinib

First Posted Date: 2006-09-11

Last Posted Date: 2014-08-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 3166

Registration Number: NCT00374322

Locations: 🇬🇧
GSK Investigational Site, Shrewsbury, United Kingdom

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome

Phase 4

Completed

Conditions: Restless Legs Syndrome (RLS)
Restless Legs Syndrome

First Posted Date: 2006-09-08

Last Posted Date: 2016-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 39

Registration Number: NCT00373542

Locations: 🇺🇸
GSK Investigational Site, Walla Walla, Washington, United States

HLA-B*5701 And Hypersensitivity To Abacavir

Completed

Conditions: HIV Infection

First Posted Date: 2006-09-08

Last Posted Date: 2009-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 280

Registration Number: NCT00373945

Locations: 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States

A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Pain

Interventions: Drug: GW406381

First Posted Date: 2006-09-07

Last Posted Date: 2017-09-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00373243

Locations: 🇭🇺
GSK Investigational Site, Budapest, Hungary

Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of The Knee

Phase 1

Completed

Conditions: Osteoarthritis

First Posted Date: 2006-09-07

Last Posted Date: 2008-10-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00372801

Locations: 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy